EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.
By Michael Weller, M. J. van den Bent, K. Hopkins, J. Tonn, R. Stupp, A. Falini, E. Cohen‐jonathan‐moyal, D. Frappaz, R. Henriksson, C. Balañà and 5 more. The Lancet Oncology, 2014
704 citations recorded by the source corpus.
Subfields: Genetics, Pediatrics, Perinatology and Child Health, Surgery
View Paper: https://www.semanticscholar.org/paper/432f5161fa7e2ec962ba64847224b9cdb4282001
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. (2016, methodology): “To date, standard, structural MRI is the most important diagnostic tool for assessing treatment effects in patients with gliomas.(4) The extent of contrast enhancement on MRI is usually considered an indicator of treatment response (eg, Macdonald criteria, RANO criteria),(5,57) although its reliabil”